Cancer market

Cancer – a debilitating disease

Cancer is a disease that involves an uncontrolled growth of cells, which leads to

tumor formation. Albeit not all tumors are cancer like benign tumors. The
abnormal tumour cells have the propensity to extend to other local tissues and may
also escalate to various parts of the body via blood and lymphatic system. There
are different types of cancers in the cancer market, such as lung cancer, colorectal,
breast cancer, and many others. Cancer treatment is based on the stages of disease
development. Chemotherapy is utilized for the majority of cases in the earlier
stages, whereas other cancer therapy options like targeted therapy drugs,
immunological therapy drugs are used in the late stage.

Cancer market driving factors

Cancer has a global prevalence that has resulted in the demand for drugs in the
cancer market. The main factors, which are responsible for the growth of the
oncology/cancer market are increase in cancer research, upsurge in geriatric
population worldwide, and increase in several collaborations between
pharmaceutical companies. Also, the rise in healthcare expenditure worldwide is
expected to boost cancer market expansion. However, high cost associated with
oncology drug development along with adverse effects associated with cancer
therapeutics is some of the factors that restrain the cancer market growth.
Conversely, the upsurge in demand for personalized medicine and high potential of
developing nations is expected to provide new opportunities for the cancer market
players in future.

Cancer Market Segmentation

The cancer market is segmented based on

 Drug class type
 Indication

Based on drug class type, the cancer market is divided into chemotherapy, targeted
therapy, immunotherapy (biologic therapy), hormonal therapy, and others.
By indication, it is categorized into lung cancer, stomach cancer, colorectal cancer,
breast cancer, prostate cancer, liver cancer, oesophagus cancer, cervical cancer,
kidney cancer, bladder cancer, and many other cancers.

The cancer market is also segmented based on

 Application
 Top-selling drugs
 Region.

Based on application, the cancer market is divided into blood cancer, lung cancer,
colorectal cancer, prostate cancer, breast cancer, cervical cancer, head & neck
cancer, glioblastoma, malignant meningioma, mesothelioma, melanoma, and
others.

By top-selling drugs, it is categorized into Revlimid, Avastin, Herceptin, Rituxan,

Opdivo, Gleevec, Velcade, Imbruvica, Ibrance, Zytiga, Alimta, Xtandi, Tarceva,
Perjeta, Temodar, and many others.

By region, Asia-Pacific is expected to witness noticeable growth shortly. In Asia,

China, India, and Japan will continue to be the fastest-growing cancer markets. The
growth in Asia-Pacific cancer market is expected to be driven by increasing
tobacco consumption, growing population, and increasing disposable income.
Moreover, high cancer market growth potential in developing nations, rise in
several pipeline products, and a rise in demand for personalized medicines are
expected to create new opportunities for the cancer market players during the
forecast period. Though, adverse effects associated with the use of cancer drugs
and high costs related to cancer drug development are the main factors that halt the
growth of the cancer market. Rise in cancer prevalence, the increase in association
between pharmaceutical companies, and the upsurge in cancer research are the
significant factors that elevate the growth of the cancer therapeutics market.
Furthermore, growth in the geriatric population is expected to boost cancer market
growth.